louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00907244: Arterial Spin Labeling Perfusion Magnetic Resonance (MR) Imaging in Pediatric Brain Tumors
Official title: CHP-901:Arterial Spin Labeling Perfusion MR Imaging in Pediatric Brain Tumors
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Brain Tumors
Lead sponsor: Children's Hospital of Philadelphia
Sponsor class: OTHER
Collaborators: name: Thrasher Research Fund
First posted: 2009-05-22
Enrollment: 13
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients between 0-18 years who are diagnosed with primary brain tumor, undergoing MRI for clinical purpose are eligible for the study.

Brief summary: The purpose of this study is to get information regarding the usefulness and accuracy of this new magnetic resonance imaging (MRI) technique - termed arterial spin labeling (ASL) - in the diagnosis of pediatric brain tumors.

Detailed description: The purpose of this study is to get information regarding the usefulness and accuracy of this new MRI technique - termed arterial spin labeling (ASL) - in the diagnosis of pediatric brain tumors. This technique can non-invasively measure the blood flow to the brain during MRI examination. Because aggressive brain tumors require new blood vessels and a high level of blood supply to support its growth, we believe the tumor blood flow measured using ASL is a reliable indicator of tumor grade. This information may be useful for doctors to make treatment decisions and to monitor patients' response to treatment.

Eligibility criteria: Inclusion Criteria:

* Age 0-18 years
* Primary brain tumor (newly diagnosed or recurrent) with measurable disease (at least 1cm2)

Exclusion Criteria:

* Patients with cardiac pacemaker or ferrous metal foreign bodies
* Patients with medical problems contradictive to receiving MRI scans.
* Patients requiring general anesthesia or sedation for their MRI scan.
* Patients with a history of cerebrovascular disorders (stroke, moya moya) that may alter cerebral perfusion.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: The Children's Hospital of Philadelphia
state: Pennsylvania
Study officials:
affiliation: Children's Hospital of Philadelphia
name: Michael Fisher, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05124444: TOlerance MOlecular and Genome-wide Studies With Renal Allograft Recipient Material
Official title: TOlerance MOlecular and Genome-wide Studies With Renal Allograft Recipient Material
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Kidney Transplantation
Lead sponsor: Université Libre de Bruxelles
Sponsor class: OTHER
Collaborators: name: DESCARTES Working Group On Transplantation
First posted: 2021-11-18
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: 1. Exome-wide association study
2. Transcriptomic analyses
Primary purpose: BASIC_SCIENCE

Brief summary: TOMOGRAM is a European multicentric, prospective, experimental, controlled study that aims to increase our understanding of the causative mechanisms of operational tolerance in kidney transplantation through the achievement of several multimodal whole-genomic analysis in human biological samples.


Eligibility criteria: Inclusion Criteria:

* recipient of an allogenic renal allograft,
* have experienced (whatever ongoing or not) at least a whole year with blood creatinine \<1.7 mg/dL and proteinuria \</=1g/day or /g creatinine despite the COMPLETE discontinuation of immunosuppressive drugs,
* alternatively, have experienced (whatever ongoing or not) at least a whole year with stable blood creatinine (max 20% variation) and proteinuria above these criteria despite the COMPLETE discontinuation of immunosuppressive drugs

Exclusion Criteria:

* Past medical history of allogeneic bone-marrow transplantation / combined organ transplantation

Primary outcomes:
measure: Number of moderately to highly damaging exonic variants
timeFrame: Through study completion, an average of 2 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02159144: Cold Stress Stimulate the Browing of Subcutaneous White Adipose in Healthy Adults
Official title: Cold Stress Stimulate the Browing of Subcutaneous White Adipose in Healthy Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Type 2 Diabetes
Keywords: Brown adipose tissue
Subcutaneous white adipose tissue
White adipose tissue
Lead sponsor: Wuhan General Hospital of Guangzhou Military Command
Sponsor class: OTHER
First posted: 2014-06-09
Enrollment: 10
Sex: MALE
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: Adipose tissues, which include white adipose tissue (WAT) and brown adipose tissue (BAT), play an essential role in regulating whole-body energy homeostasis. Recent studies also reveal the presence of a subset of cells in WAT that could be induced by environmental or hormonal factors to become ''brown-like'' cells, and this ''beigeing'' process has been suggested to have strong antiobesity and antidiabetic benefits. More recently, same studies showed that cold stress stimulate the browning of subcutaneous white adipose. However, to the investigators knowledge, there are no direct data that clearly show that cold stress can promote the browning of subcutaneous white adipose.

Detailed description: Individuals have cold exposure at 15C for 2 hr everyday for one week.Biopsy for subcutaneous white adipose was performed before and after one week cold exposure programme under local anesthesia. Measure the brown fat characteristics of biopsy samples. The expression levels of uncoupling protein-1 (UCP-1), peroxisome proliferator-activated receptor (PPAR)-r, peroxisome proliferator-activated receptor r coactivator 1 a (PGC1a) , growth factor receptor binding protein-10 (Grb10), PR domain containing 16 (PRDM16) will be determined before and after cold stress programme from the biopsy samples. In addition, a combination of PET and computed tomography (CT) - with the glucose analogue 18F-fluorodeoxyglucose (18F-FDG) as a tracer will be performed for brown adipose tissue before and after cold stress programme.

Eligibility criteria: Inclusion Criteria:

* healthy men
* 18-60 years old
* BMI 20-28 kg/m2

Exclusion Criteria:

* BMI \< 20 kg/m2
* BMI \> 28 KG/M2
* Female

Primary outcomes:
measure: browning of subcutaneous white adipose
timeFrame: 4 months
Secondary outcomes:
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Wuhan General Hospital
state: Hubei
Study officials:
References:
Clinical trial NCT00605644: Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chronic Non-Malignant Pain
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Nonmalignant Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Constipation
Lead sponsor: Bausch Health Americas, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Progenics Pharmaceuticals, Inc.
First posted: 2008-01-31
Enrollment: 128
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary purpose of this study is to evaluate the safety and dose-response relationship of N-methylnaltrexone bromide (MOA-728) by observing spontaneous bowel movements in subjects administered MOA-728 who have chronic pain that is not due to cancer, and who have opioid-induced bowel dysfunction (OIBD).


Eligibility criteria: Inclusion Criteria:

* Adult Outpatients with opioid-induced bowel dysfunction and chronic pain, which is not due to malignant cancer.
* Taking oral, transdermal, intravenous, or subcutaneous opioids.
* Willingness to discontinue all pre-study laxative therapy and use only study permitted rescue laxatives.

Exclusion Criteria:

* History of chronic constipation before the initiation of opioid therapy.
* Other GI disorders known to affect bowel transit.
* Women who are pregnant, breast feeding, or plan to become pregnant.

Primary outcomes:
measure: Percentage of Participants Witn Spontaneous Bowel Movements Within 3 Hours of Treatment
timeFrame: 3 hours
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Bausch Health Americas, Inc.
name: Jeff Cohn
role: STUDY_DIRECTOR
References:
Clinical trial NCT01349244: Hydronephrosis on Ultrasound With CT Finding in Patients With Renal Colic
Official title: Correlation of Hydronephrosis on Point of Care Ultrasound With CT Finding in Patients With Expected Renal Colic
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hydronephrosis
Renal Colic
Keywords: hydronephrosis
CT
POC US
Lead sponsor: Yale University
Sponsor class: OTHER
First posted: 2011-05-06
Enrollment: 97
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This will be a prospective observational study involving a convenience sample of all ED patients scheduled for NCT at some point during their emergency department visit.

Brief summary: The purpose of this study is to determine the overall sensitivity and specificity of hydronephrosis on point-of-care bedside ultrasound to identify hydronephrosis as compared to hydronephrosis found by CT.


Eligibility criteria: Inclusion Criteria:

* Emergency Department patients 18 yrs or older with suspected renal colic in whom the clinician intends to obtain a CT scan to diagnose kidney stone.
* Informed consent will be required prior to enrollment in the study.

Exclusion Criteria:

* Known renal disease (any ESRD, transplant, PCKD), dementia, trauma, language barrier, incarcerated patients, and patients who do not undergo CT.

Primary outcomes:
measure: hydronephrosis bedside ultrasound
timeFrame: Sept 2011-Jan 2013
Secondary outcomes:
measure: hydronephrosis bedside ultrasound
timeFrame: Sept 2011-Jan 2013
Other outcomes:
measure: hydronephrosis
timeFrame: Sept 2011-Jan 2013
Locations:
city: New Haven
country: United States
facility: Yale University, Emergency Department
state: Connecticut
Study officials:
affiliation: Yale University
name: Christopher L Moore, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00128544: Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B
Official title: A Randomized, Blinded, Phase IIb Trial of Telbivudine (LdT) Versus the Combination of Telbivudine and Valtorcitabine (Val-LdC) in Patients With Chronic Hepatitis B
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Hepatitis B
Lead sponsor: Novartis
Sponsor class: INDUSTRY
Collaborators: name: Novartis Pharmaceuticals
First posted: 2005-08-10
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is being conducted to compare the effectiveness of the combination of valtorcitabine and telbivudine to telbivudine alone in patients with chronic hepatitis B.


Eligibility criteria: Inclusion Criteria:

* Clinical history compatible with compensated chronic hepatitis B

Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Patient is pregnant or breastfeeding
* Patient is co-infected with hepatitis C virus, hepatitis D virus or HIV
* Patient has previously received lamivudine, adefovir dipivoxil or an investigational anti-hepatitis B virus (HBV) nucleoside or nucleotide at anytime.

Other protocol-defined exclusion criteria may apply.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Pokfulam
country: Hong Kong
city: Auckland
country: New Zealand
city: Singapore
country: Singapore
Study officials:
References:
Clinical trial NCT05842044: NSAID Use After Robotic Partial Nephrectomy
Official title: NSAID Use After Robotic Partial Nephrectomy (No-PAIN): a Randomized, Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Kidney Cancer
Renal Cancer
Renal Neoplasm
Keywords: Non-steroidal anti-inflammatory drugs (NSAIDs)
Lead sponsor: University of Miami
Sponsor class: OTHER
First posted: 2023-05-03
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to see how effective non-steroidal anti-inflammatory drugs (NSAIDs) are at controlling pain without side effects in participants after robotic-assisted partial nephrectomy.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing uncomplicated robotic assisted laparoscopic partial nephrectomy for renal mass at the University of Miami Hospital and Network Sites (Deerfield Beach, Plantation, Lennar (Coral Gables), and Kendal).
* Age 18-99.
* Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* Allergy to NSAIDs
* Myocardial infarction or unstable angina within 12 months.
* Any history of coronary artery bypass graft surgery.
* History or active peptic ulcer disease, gastrointestinal (GI) bleeding, GI perforation. History of bleeding disorder. Glomerular filtration rate (GFR) \< 60 mL/min/1.73m2 (Modification of Diet in Renal Disease (MDRD) equation).
* Taking any anti-platelet or anti-coagulation medications concurrently (e.g. warfarin, aspirin, clopidogrel, rivaroxaban etc.)
* Chronic opioid use (use within 12 weeks) or history of opioid use disorder.
* Solitary kidney.
* Pregnancy.
* Inability to give informed consent or unable to meet requirement of the study for any reason.

Primary outcomes:
measure: Rate of Opioid Use in Postoperative Period
timeFrame: Up to 20 days
Secondary outcomes:
measure: Rate of Opioid Medication Use during Hospitalization
timeFrame: Up to 24 hours
measure: Pain Score Assessed by Standardized Script
timeFrame: Up to 20 days
measure: Pain Score Assessed by International Pain Outcome Questionnaire
timeFrame: Up to 20 days
measure: Number of Treatment-Related Adverse Events
timeFrame: Up to 20 days
measure: Change in Rate of Acute Kidney Injury
timeFrame: Baseline, Up to 20 days
Other outcomes:
Locations:
city: Miami
country: United States
facility: University of Miami
state: Florida
Study officials:
affiliation: University of Miami
name: Mark L Gonzalgo, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00154544: Searching for the Liver Cancer-Related Biomarkers
Official title: Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by PROTEOMEX
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hepatocellular Carcinoma
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2005-09-12
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: DEFINED_POPULATION
Time perspective: OTHER

Brief summary: Hepatocellular carcinoma (HCC) has been the leading cause of cancer death in Taiwan. About 6000-8000 people died of this cancer every year in Taiwan. Though regular sonographic examination can early detect small HCC and there are many therapeutic modalities for HCC, the therapeutic results remains unsatisfactory. Though Alpha-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) are used as the tumor markers for diagnosis of HCCs, these two markers are not good enough for the early detection of small HCCs. To improve the survival, further investigations of the early diagnostic markers are still needed. In this current project, we applied the proteomic method to identify the HCC biomarkers.

Detailed description: Cell lines Hep3B and Huh7 HCC cell lines will be cultured in (Dulbecco's modified Eagle medium) DMEM containing 10% fetal calf serum and incubated at 37 C in 5% CO2 incubator. The rationale of using HCC cell line instead of clinical HCC samples is that HCC tissues are heterogeneous and might contain some non-HCC cells. The cell will be harvested when cells reach 95% confluence.

Sera collection 20 mL of venous 20 mL of venous blood was collected from 20 HBV-related HCC and 20 HCV-related HCC patients before treatment. The venous blood was allowed to clot, centrifuged at 800 g for 5 min, and serum was aliquoted and stored at -80 0C. Control sera were obtained from 20 HBV carriers without HCC, 20 chronic hepatitis C patients without HCC, and 10 normal subjects without liver diseases.

Two-dimensional gel electrophoresis using patients' sera for immunoblotting will be done. Spots of interest will be identified by delayed extraction matrix-assisted laser desorption ionization.

Eligibility criteria: Inclusion Criteria:

* hepatocellular carcinoma

Exclusion Criteria:

* multiple cancers

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Chien-Hung Chen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03355144: Resident Observed Burnout After Daily Supplementation With Coffee
Official title: Resident Observed Burnout After Daily Supplementation With Coffee
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Burnout, Professional
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2017-11-28
Enrollment: 39
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Coffee drinking is frequently reported as a negative outcome in studies on burnout, but the effect of an increased coffee intake on resident burnout has not been reported in the literature. This study is a prospective, interventional cohort study enrolling up to 50 residents from the Internal Medicine Residency Program to look at the relationship between coffee and resident burnout.

Detailed description: Resident burnout is increasingly being recognized as detrimental to both physician well being and patient care. It has been linked to an increased rate of medical errors and a reduced quality of patient care. In addition, there have been multiple high-profile physician suicides in the past years. This has resulted in a renewed focus on physician mental health and workload.

Eligibility criteria: Inclusion Criteria:

* A resident in the NYU Internal Medicine residency program

Exclusion Criteria:

* Allergy or intolerance to coffee or caffeine
* Pregnancy

Primary outcomes:
measure: Self reported feelings of burnout
timeFrame: 1 Month
Secondary outcomes:
measure: Coffee consumption measured by self reporting questionaire
timeFrame: 1 Month
measure: Self reported emotional well being
timeFrame: 1 Month
measure: Self reported feelings of value
timeFrame: 1 Month
Other outcomes:
Locations:
city: New York
country: United States
facility: New York University School of Medicine
state: New York
Study officials:
affiliation: NYU Langone Health
name: Steven Liu, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04087044: Computerized Rotational Head Impulse Test-Vertical (crHIT-vertical)
Official title: Computerized Rotational Head Impulse Test-Vertical (crHIT-vertical)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Vestibular Function Tests
Keywords: vestibular neuritis
vestibular migraine
Lead sponsor: Neurolign
Sponsor class: INDUSTRY
Collaborators: name: University of Miami
name: University of Pittsburgh
name: Mayo Clinic
First posted: 2019-09-12
Enrollment: 186
Sex: ALL
Minimum age (years): 22
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 66 patients (30 patients with surgically confirmed unilateral loss, 15 patients with absent ice water calorics and resulting from vestibular neuritis and 21 patients with vestibular migraine) 120 controls
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this research study is to test whether a Computerized Rotational Head Impulse Test-Vertical (crHIT-vertical) is able to reliably evaluate the vertical semicircular canals in patients with vestibular dysfunctions.


Eligibility criteria: Inclusion Criteria:

* Subjects must be willing to tolerate the placement of a set of goggles on their face
* Controls:

  1. no history of dizziness or imbalance
  2. normal responses on rotational chair testing
* Patients: persons clinically diagnosed with vestibular disorders

Exclusion Criteria:

* Pregnancy
* Neurodegenerative diseases

Primary outcomes:
measure: Sensitivity and specificity of crHIT-vertical
timeFrame: 9 months
Secondary outcomes:
measure: Subject discomfort - symptoms
timeFrame: 9 months
measure: Subject discomfort - test apparatus
timeFrame: 9 months
Other outcomes:
Locations:
city: Miami
country: United States
facility: University of Miami
state: Florida
city: Rochester
country: United States
facility: Mayo Clinic Rochester
state: Minnesota
city: Pittsburgh
country: United States
facility: University of Pittsburgh
state: Pennsylvania
Study officials:
affiliation: University of Miami
name: Michael E Hoffer, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Pittsburgh
name: Joseph Joseph Furman, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Mayo Clinic
name: Devin McCaslin,, PhD
role: PRINCIPAL_INVESTIGATOR
References: